Literature DB >> 14745033

Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.

Jacob Bukczynski1, Tao Wen, Kim Ellefsen, Jack Gauldie, Tania H Watts.   

Abstract

Effective adjuvants capable of inducing strong cytotoxic T cell responses in humans are lacking. In this study, we tested 4-1BBL as an adjuvant for activation of human memory antiviral CD8 T cell responses ex vivo. A recombinant replication-defective 4-1BBL adenovirus was used to convert autologous monocytes into efficient antigen-presenting cells after overnight incubation, bypassing the need to generate dendritic cells. Together with viral peptides, 4-1BBL led to robust memory responses of human Epstein-Barr virus- and influenza virus-specific cytotoxic T cells, with expansion of peptide-specific CD8 effector cells; up-regulation of Bcl-x(L), granzyme A, and perforin; enhanced cytotoxic activity; and increased cytokine production. The response was significant even at a 100-fold lower peptide dose, compared with responses obtained with control adenovirus. Adenovirus-delivered B7.1 also expanded and activated virus-specific CD8 T cells, but 4-1BBL was more effective in driving the T cells toward a more fully differentiated CD27(-) effector state. Thus, 4-1BBL is a promising adjuvant for human memory CD8 T cells and will likely be most effective in the boost phase of a prime-boost strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745033      PMCID: PMC337046          DOI: 10.1073/pnas.0306567101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

3.  Down-regulation of CD28 expression by TNF-alpha.

Authors:  E Bryl; A N Vallejo; C M Weyand; J J Goronzy
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

4.  4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Authors:  J L Cannons; P Lau; B Ghumman; M A DeBenedette; H Yagita; K Okumura; T H Watts
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function.

Authors:  A D Hislop; N H Gudgeon; M F Callan; C Fazou; H Hasegawa; M Salmon; A B Rickinson
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

6.  4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination.

Authors:  J T Tan; J K Whitmire; K Murali-Krishna; R Ahmed; J D Altman; R S Mittler; A Sette; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

7.  Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis.

Authors:  N J Borthwick; M Lowdell; M Salmon; A N Akbar
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

8.  Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.

Authors:  M A DeBenedette; T Wen; M F Bachmann; P S Ohashi; B H Barber; K L Stocking; J J Peschon; T H Watts
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

9.  Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response.

Authors:  J L Cannons; Y Choi; T H Watts
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

10.  HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Authors:  V Appay; D F Nixon; S M Donahoe; G M Gillespie; T Dong; A King; G S Ogg; H M Spiegel; C Conlon; C A Spina; D V Havlir; D D Richman; A Waters; P Easterbrook; A J McMichael; S L Rowland-Jones
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  42 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.

Authors:  Yuwen Zhu; Gefeng Zhu; Liqun Luo; Andrew S Flies; Lieping Chen
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

Review 3.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

6.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

7.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

8.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

9.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

10.  Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.

Authors:  Gloria H Y Lin; Yuanqing Liu; Thanuja Ambagala; Byoung S Kwon; Pamela S Ohashi; Tania H Watts
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.